Beijing and Heidelberg, June 3, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) today announced 3 poster presentations for two novel fully human antibody platforms and one bispecific antibody-drug conjugate (ADC) asset at the 2022 Antibody Engineering & Therapeutics Europe (AET-EU) meeting, taking place on June 7-9 in Amsterdam and online. The antibody business development & licensing team from Biocytogen Europe Innovation Center (BEIC) will be onsite at booth #3 and will also present posters.

One of the posters will introduce Biocytogen’s RenMice™ HiTS (Hyperimmune Target Specific) Platform, also called Project Integrum, used for identification of new therapeutic antibodies. The BEIC team will present the current progress of this platform, which involves knocking out 1000+ potentially druggable targets in fully human antibody RenMice™ (RenMab™ and RenLite®) for the purpose of generating fully human antibodies covering diverse epitopes with high affinity and specificity. Combined with downstream high-throughput in vivo efficacy screening capabilities, Project Integrum offers a streamlined solution to develop antibodies that recognize novel and challenging targets.

The BEIC team will also present Biocytogen’s novel TCR-mimic platform for discovering fully human antibodies against intracellular targets. The platform utilizes HLA-expressing fully human antibody mice (HLA/RenMab mice) to generate antibodies binding intracellular tumor-associated antigens in the context of HLA when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform enables swift identification of TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody hits for multiple intracellular targets are undergoing in vitro and in vivo characterization. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.

A preclinical candidate YH012 will also be introduced. YH012 is a HER2 x TROP2 bispecific ADC generated from Biocytogen’s proprietary bsADC platform, leveraging the common light chain RenLite® mice to acquire bispecific antibodies with high affinity and specificity as well as good stability for downstream drug conjugation. In vivo drug efficacy data shows potent anti-tumor activity.

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company’s pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. 

For more information, please contact:

Antibody assets:

Vivian Tian, PhD, MBA

Email: [email protected]

Office: +86 010-56967680


Zimeng Zhang, PhD

Email: [email protected]

Office: +86 010-56967680

Back to top